Company Analysis Merit Medical Systems, Inc.
1. Summary
Advantages
- The stock's return over the last year (31.82%) is higher than the sector average (-21.54%).
Disadvantages
- Price (100.45 $) is higher than fair price (32.8 $)
- Dividends (0%) are below the sector average (0.5351%).
- Current debt level 35.91% has increased over 5 years from 25.01%.
- The company's current efficiency (ROE=7.85%) is lower than the sector average (ROE=9.78%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Merit Medical Systems, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.9% | -20.4% | -2.4% |
| 90 days | -3.1% | -22.2% | -8.5% |
| 1 year | 31.8% | -21.5% | 12.3% |
MMSI vs Sector: Merit Medical Systems, Inc. has outperformed the "Healthcare" sector by 53.36% over the past year.
MMSI vs Market: Merit Medical Systems, Inc. has outperformed the market by 19.55% over the past year.
Stable price: MMSI is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MMSI with weekly volatility of 0.612% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (100.45 $) is higher than the fair price (32.8 $).
Price is higher than fair: The current price (100.45 $) is 67.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (46.72) is lower than that of the sector as a whole (57.27).
P/E vs Market: The company's P/E (46.72) is lower than that of the market as a whole (49.14).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.67) is lower than that of the sector as a whole (4.64).
P/BV vs Market: The company's P/BV (3.67) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.52) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (3.52) is lower than that of the market as a whole (10.29).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (21.12) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (21.12) is lower than that of the market as a whole (25.46).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -211.83% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-211.83%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (106.41%).
5.4. ROE
ROE vs Sector: The company's ROE (7.85%) is lower than that of the sector as a whole (9.78%).
ROE vs Market: The company's ROE (7.85%) is lower than that of the market as a whole (8.96%).
5.5. ROA
ROA vs Sector: The company's ROA (4.06%) is higher than that of the sector as a whole (0.33%).
ROA vs Market: The company's ROA (4.06%) is lower than that of the market as a whole (6.33%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5351%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 53.4% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 28.02.2025 | Gunderson Thomas James Director |
Purchase | 50.5 | 1 262 500 | 25 000 |
| 28.02.2025 | Parra Raul Jr. CFO AND TREASURER |
Sale | 98.81 | 1 230 280 | 12 451 |
| 28.02.2025 | Voigt Michel James CHIEF HUMAN RESOURCES OFFICER |
Sale | 99.68 | 1 376 480 | 13 809 |
| 28.02.2025 | Voigt Michel James CHIEF HUMAN RESOURCES OFFICER |
Purchase | 61.42 | 848 149 | 13 809 |
| 28.02.2025 | LAMPROPOULOS FRED P President and CEO |
Purchase | 44.8 | 179 200 | 4 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
